Quantitative immunohistochemistry and the use of cellular calibrators for HER2 receptor number determination
Authors:
Open Access
- 23 March 2026
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Abstract
It is suggested that high error rates in clinical IHC compared to other laboratory disciplines are due to a lack of traceable analytic standards with quantitative controls. Quantitative controls can be achieved by implementing calibrators into IHC workflows, but recently published approaches offer little discussion about what the ideal calibrator should look like. Here, we detail an IHC method that utilizes cellular calibrators to determine the average number of HER2 receptors in tumor cells of breast cancer tissue. Electrochemiluminescent immunoassay and flow cytometry were used to establish nominal HER2 amounts in the cellular calibrators. The quantitated number of HER2 receptors and associated 4B5 scores from commercially sourced breast cancer tumors were compared. The results were discordant, indicating differences in analytical performance. Cells are ideal calibrators for IHC because the antigens they express are structurally and functionally representative of the endogenous analyte being measured. They can also be stained and analyzed identically to tissues, and are easily cultured, expanded, and manipulated. However, novel methods for labeling cells with fixed amounts of proteins are needed. In addition, standards for validation of quantitative IHC methods should be developed and their clinical utility must be demonstrated.Keywords
Funding Information
- GlaxoSmithKline
This publication has 26 references indexed in Scilit:
- Validation and Prospective Testing of a High-Sensitivity, Quantitative Analytic Assay for HER2 on Histopathology SlidesLaboratory Investigation, 2025
- HER2 testing: evolution and update for a companion diagnostic assayNature Reviews Clinical Oncology, 2025
- Interobserver consistency and diagnostic challenges in HER2-ultralow breast cancer: a multicenter studyESMO Open, 2025
- Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancerLaboratory Investigation, 2022
- Cross-platform comparison of highly sensitive immunoassay technologies for cytokine markers: Platform performance in post-traumatic stress disorder and Parkinson’s diseaseCytokine: X, 2020
- Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarrayLaboratory Investigation, 2020
- Development of a highly specific HER2 monoclonal antibody for immunohistochemistry using protein microarray chipsBiochemical and Biophysical Research Communications, 2017
- Evaluation of highly sensitive immunoassay technologies for quantitative measurements of sub-pg/mL levels of cytokines in human serumJournal of Immunological Methods, 2016
- Proficiency testing in immunohistochemistry—experiences from Nordic Immunohistochemical Quality Control (NordiQC)Virchows Archiv, 2015
- Diagnostic Immunohistochemistry: What can Go Wrong?Advances in Anatomic Pathology, 2006